Skip to content
Open access · CC-BY via OpenAlex

Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy

Alba Rodríguez-García, Raquel Ancos-Pintado, Roberto García-Vicente, Alejandra Ortiz-Ruiz, Andrés Arroyo, Miguel Angel Navarro, María Luz Morales, Patricia Guevara‐Ramírez, Pablo Justo, Nieves López‐Muñoz, José María Sánchez‐Pina, Rafael Alonso, Maria Victoria Selma, María Dolores Frutos-Lisón, Rocío García-Villalba

Microbiome · 2025 · ▲ 20 citations

Abstract

BACKGROUND: Gut microbiota-derived urolithins may influence multiple myeloma (MM) disease progression and treatment. We analyzed urolithins and their associated microbiota in a retrospective cohort of 45 patients with active MM or premalignant disease using mass spectrometry and 16S rRNA gene sequencing. RESULTS: Patients with detectable levels of urolithin in serum and stool and a higher abundance of urolithin-related microbiota had a better outcome. Analysis of the effects of urolithin A (UroA) treatment ex vivo, in vitro, and in vivo revealed that UroA is cytotoxic against MM cell lines and modulates the cell cycle and mitochondrial activity. Notably, UroA inhibits the proliferation of primary MM cells in vitro and in a xenograft mouse model, improving overall survival. Finally, combination therapy with UroA and bortezomib has a synergistic effect in vitro, even in the presence of bortezomib resistance, and modulates signaling pathways involved in MM development. CONCLUSIONS: UroA might be a potential therapeutic agent to halt MM disease progression or to overcome resistance when used in combination. Video Abstract.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1186/s40168-025-02045-6
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Rodríguez-García, A., Ancos-Pintado, R., García-Vicente, R., Ortiz-Ruiz, A., Arroyo, A., Navarro, M.A., Morales, M.L., Guevara‐Ramírez, P., Justo, P., López‐Muñoz, N., Sánchez‐Pina, J.M., Alonso, R., Selma, M.V., Frutos-Lisón, M.D., García-Villalba, R., Tomás-Barberán, F.A., Ayala, R.M., Martínez‐López, J., &amp; Linares, M.J.P. (2025). Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy. <em>Microbiome</em>. https://doi.org/10.1186/s40168-025-02045-6
Vancouver
Rodríguez-García A, Ancos-Pintado R, García-Vicente R, Ortiz-Ruiz A, Arroyo A, Navarro MA, et al. Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy. Microbiome. 2025. doi:10.1186/s40168-025-02045-6.
BibTeX
@article{alba2025Microb, title = {Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy}, author = {Alba Rodríguez-García and Raquel Ancos-Pintado and Roberto García-Vicente and Alejandra Ortiz-Ruiz and Andrés Arroyo and Miguel Angel Navarro and María Luz Morales and Patricia Guevara‐Ramírez and Pablo Justo and Nieves López‐Muñoz and José María Sánchez‐Pina and Rafael Alonso and Maria Victoria Selma and María Dolores Frutos-Lisón and Rocío García-Villalba and Francisco Abraham Tomás-Barberán and Rosa María Ayala and Joaquín Martínez‐López and María José Pedraja Linares}, journal = {Microbiome}, year = {2025}, doi = {10.1186/s40168-025-02045-6}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings